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Highlights 
 Atherosclerotic cardiovascular disease (ASCVD) is a major cause of mortality and
morbidity worldwide.
 Improved visualization of early atherosclerosis and better management of residual
risk can reduce ASCVD burden.
 Recent research has investigated the potential of biomaterials and nanomedicines
in meeting this demand.
 Liposomes have a wide range of applications in both imaging and treatment of
atherosclerosis. 
 We review the scientific and clinical evidence relating to the use of liposomes in
the context of ASCVD. 
Teaser: This review describes the experimental and clinical evidence for 
the use of liposomes in the diagnosis and management of atherosclerotic 
cardiovascular disease. 
The consequences of atherosclerotic cardiovascular disease (ASCVD) 
include myocardial infarction, ischemic stroke, and angina pectoris, which 
are major causes of mortality and morbidity worldwide. Despite current 
therapeutic strategies to reduce risk, patients still experience the 
consequences of ASCVD. Consequently, a current goal is to enhance 
visualization of early atherosclerotic lesions to improve residual ASCVD 
risk. The uses of liposomes, in the context of ASCVD, can include as 
contrast agents for imaging techniques, as well as for the delivery of 
antiatherosclerotic drugs, genes, and cells to established sites of plaque. 
Additionally, liposomes have a role as vaccine adjuvants against 
mediators of atherosclerosis. Here. we review the scientific and clinical 
evidence relating to the use of liposomes in the diagnosis and 
management of ASCVD. 
Keywords: atherosclerosis treatment; atherosclerosis diagnosis; liposome; 
nanoliposome; plaque. 
Introduction 
The consequences of ASCVD include myocardial infarction, ischemic 
stroke, and angina pectoris, which are major causes of mortality and 
morbidity worldwide [1]. One of the most important risk factors for the 
development of ASCVD is life-long exposure to elevated circulating 
concentrations of apolipoprotein-B (apoB)-containing lipoproteins, such as 
low-density lipoprotein (LDL) cholesterol [2]. Additional risk factors for 
ASCVD include smoking, hypertension, diabetes, abdominal obesity, and 
physical inactivity [1]. 
Atherosclerosis is a progressive lipid-driven, inflammatory disease that 
can be divided conceptually into various stages. The early stages of the 
disease are characterized by vascular endothelial dysfunction. Leukocytes 
are recruited to the endothelium and express proinflammatory cytokines. 
This is followed by the infiltration of monocytes into the vascular wall and 
their maturation into macrophages, which incorporate lipids and become 
foam cells. The next step in the atherogenic cascade involves the 
infiltration of smooth muscle cells into the intima. As plaques further 
develop and mature, they ultimately restrict blood flow by reducing the 
diameter of the lumen and are prone to rupture. Subsequent rupture 
exposes the highly thrombogenic plaque contents to the blood, which 
results in intravascular thrombus formation [3,4]. 
Looking more closely at the series of steps in atheroma formation 
reveals that an initial step includes inflammation and the release of 
inflammatory cytokines, which results in the overexpression of cell 
adhesion molecules, such as selectin and vascular cell adhesion molecule-
1 (VCAM-1, also known as CD106), on the vascular endothelial cell 
surface. This causes endothelial dysfunction, which predisposes the 
individual to the permeation of lipoproteins, as well as the recruitment of 
T cells and monocytes, into the vascular wall. Subsequently, the recruited 
monocytes differentiate into macrophages. These phagocytic cells not only 
promote further inflammation, but also activate the endothelium by 
releasing proteases, growth factors, interleukins, and prostaglandins. 
Plaques then form on the tunica intima, the innermost lining of the 
vessels. Thickening of the intimal layer of the vessel, which follows plaque 
formation, diminishes the diffusion of oxygen across the vessel wall. This 
leads to local hypoxia, which stimulates neovascularization and further 
promotes plaque progression. Furthermore, oxidative stress activates 
nuclear factor B (NF-B) within the endothelial cells. Activation of NF-
B increases the expression of cell adhesion molecules and leads to a
vicious cycle of disease progression [2,5].
In advanced atherosclerotic lesions, a large number of lipids and 
necrotic cells are evident. The plaques contain a lipid core and a fibrous 
cap containing type 1 collagen. Measuring the collagen content of the 
plaques provides valuable information concerning plaque stability. 
Plaques that are susceptible to rupture are generally uncalcified and have 
a thin fibrous cap and a large lipid core [6]. Plaque rupture typically 
occurs following the accumulation of macrophages behind the fibrous cap 
and their subsequent conversion to foam cells, which are formed when 
macrophages engulf aggregated oxidized LDL in the core. Given that foam 
cells express collagenases that damage the fibrous cap, the plaques 
become swollen and inflamed, and subsequently rupture [7,8]. The 
rupture of atherosclerotic plaques in coronary and carotid arteries leads to 
myocardial infarction and ischemic stroke, respectively [9]. 
In recent years, impressive advances have been made in cardiovascular 
risk prediction, and risk factor management. However, risk calculators, 
such as Framingham [10], ASCVD [11], and QRISK-3 [12], do not always 
identify as ‘high-risk’ those individuals who later experience 
cardiovascular events despite the fact that atherosclerosis is a progressive 
pathology with early physical manifestations evident in the vasculature 
even in young adults. Furthermore, despite guideline-driven risk factor 
management, patients still experience the consequences of ASCVD, 
because of ‘residual risk’, which is not managed even by optimal use of 
current medication [13]. Consequently, improved visualization of the early 
stages of atherosclerosis, and better management of residual risk, have 
the potential to reduce the burden of ASCVD. 
Liposomes are biocompatible and nontoxic structures, comprising 
phospholipids, which self-assemble in water and form layered vesicles. 
Multilamellar vesicles with a size range of 0.1–10 mm contain more than 
one concentric lamellar bilayer, whereas unilamellar vesicles contain one 
concentric lamellar bilayer. Unilamellar vesicles can be categorized by 
size into small unilamellar vesicles (SUVs) (<100 nm), large unilamellar 
vesicles (LUVs) (100–500 nm), and giant unilamellar vesicles (GUVs) (>1 
mm) [14]. Multilamellar liposomes can be passed through a series of
polycarbonate filter membranes to produce unilamellar liposomes [15].
Since their discovery during the 1960s, liposomes have proven useful in a
variety of cardiovascular diseases and conditions and have potential use
in both the diagnosis and treatment of atherosclerosis [16]. Combining
liposomes with conventional diagnostic tools can improve the detection of
plaques. Combining drugs, especially anti-inflammatory agents, with
liposomes has been shown to result in improved therapeutic effects at
significantly lower doses. Here, we review scientific and clinical evidence
relating to the use of liposomes in the diagnosis and management of
ASCVD.
Targeting liposomes to atherosclerosis 
Applications of liposomes in atherosclerotic disease rely on the ability of 
liposomes to target early atherosclerotic lesions or advanced plaques, 
which permits the effective delivery of drugs, genes, cells, and contrast 
agents. Liposomes can be modified such that they have polyethylene 
glycol (PEG) on their surface, in a process called PEGylation, which is the 
attachment of PEG molecules to the liposome. This increases the time 
that liposomes reside in the circulation and increases their opportunities 
to target the plaques. A range of innovative strategies for the targeting of 
plaques by liposomes have been investigated. These strategies span the 
various stages in the progression of atherosclerosis, from targeting early 
endothelial dysfunction to lipid accumulation by macrophages and, lastly, 
targeting of vulnerable plaques on the verge of rupture, which are a 
feature of advanced atherosclerotic disease. These techniques are 
described here and are summarized in Figure 1. 
Targeting the endothelium 
The simplest way to target atherosclerotic plaques is to utilize the 
enhanced permeability and retention (EPR) of the injured endothelium in 
atherosclerosis. This effect enables nanoliposome extravasation from the 
bloodstream at the site of plaques [17]. 
As mentioned earlier, damaged endothelium overexpresses specific 
molecules, which can be used as liposome targets. The luminal 
endothelium and newly formed microvessels overexpress cell adhesion 
molecules, such as VCAM1, intercellular adhesion molecule 1 (ICAM-1), 
P-selectin, E-selectin, and alpha V beta 3 (αVβ3) integrin. Even noncellular
components of plaques, such as junctional adhesion molecules (JAMs),
which serve to direct the inflammatory cells to the atherosclerotic site,
could be a potential target for liposomes [18]. Antibodies against the
above-mentioned molecules are attached to the surface of the liposome to
target the dysfunctional endothelium. For example, liposomes containing
an anti-inflammatory agent accumulated successfully at the site of the
lesion when anti-VCAM-1 was attached to the surface of liposomes [19].
Additionally, anti-ICAM-1-decorated liposomes were found to bind
strongly to endothelial cells [20]. Attaching antibodies against E-selectin
also increased the accumulation of liposomes in endothelial cells in
atherosclerotic lesions [21].
Lectin-like oxidized LDL receptor-1 (LOX-1) is another potential target 
for liposomes because of the upregulation of this receptor on the 
endothelium following the release of inflammatory cytokines and exposure 
to oxidative stress during atherosclerosis. In fact, oxidized LDL (oxLDL) 
exerts detrimental effects during plaque formation by binding to this 
receptor [22,23]. Liposomes functionalized with an anti-LOX-1 antibody 
successfully targeted LOX-1 receptors after intravenous injection in LDL 
receptor-deficient (LDLR–/–) mice [24]. In plaques in which angiogenesis 
occurs, αvβ3 integrin (expressed in endothelial cells of neovessels), can be 
used as a target for liposomes. RGD (Arg-Gly-Asp) functionalized 
liposomes with the ability to target αvβ3 integrin have been developed to 
target tumor angiogenesis and, hence, could be utilized to target 
atherosclerotic plaques [25]. 
Although the attachment of antibodies to the surface of liposomes 
provides specific targeting, it creates a problem by increasing the immune 
recognition of the liposomes. This results in faster clearance from the 
circulation. Therefore, the density of antibodies on the liposome surface 
must be optimized to tackle this problem. A density of 70–80 mg 
antibody/mmol phospholipid, approximately equal to 30–40 antibody 
molecules per a 100 nm diameter liposome, is thought to be optimal [26]. 
Where appropriate, multiple antibodies could be attached to a single 
liposome [27,28]. 
The membrane fluidity of liposomes enables antibody mobility and 
improves binding and uptake of liposomes by inflammatory endothelial 
cells. Gunawan et al. tested differences in membrane fluidity by a method 
called fluorescence polarization. In this method, a hydrophobic 
fluorophore (BODIPY® FL) was positioned between phospholipid layers in 
the liposome structure, and the fluorescent intensity of the probe was 
measured. Probe motion within the bilayer demonstrated membrane 
fluidity and resulted in lower anisotropy values [29]. Increased expression 
of interleukin-10 (IL-10) receptors on the surface of the aortic 
endothelium in atherosclerosis is another potential liposome target. IL-10 
has important regulatory roles during inflammation and can enter the 
plaque via its receptors located on injured vascular endothelium. 
However, the short in vivo half-life of IL-10 and its limited in vivo 
stability necessitate encapsulation into biocompatible carriers, such as 
liposomes. Almer et al. incorporated IL-10 into fluorescently labeled 
liposomes and, by measuring the intensity of fluorescence, were able to 
observe increased accumulation of IL-10 in the aorta [30]. 
Despite the theoretical and experimental promise of the above-
mentioned strategies to target endothelium in atherosclerosis, 
introduction of these methods to the clinic has been problematic. For 
example, blood flow in the vessels applies shear stress to the endothelial 
wall. This can wash the particles away from the targeted site and 
decrease the time of interaction of the particles with their target in the 
plaque. However, there are some liposomal formulations that have been 
designed to release their ‘cargo’ or ‘payload’ at the plaque site despite 
abnormal blood flow and increased shear stress [31,32]. 
Targeting macrophages 
Another approach to treating atherosclerosis using liposomes is to target 
macrophages in the plaque. Previous research demonstrated that the 
existence of phosphatidylserine (PS) on the surface of apoptotic cells leads 
to their recognition and engulfment by macrophages [13,33,34]. Therefore, 
it is possible to incorporate synthetic PS into liposomes during 
manufacture to improve recognition by macrophages. Uptake of liposomes 
by macrophages brings them to the macrophage-rich site of the plaque 
[33]. To test this idea, an in vitro study of liposomal uptake by 
macrophages was performed by encapsulating 111In-nitrilotriacetic acid 
into liposomes and injecting the radiolabeled liposomes into Watanabe 
heritable hyperlipidemic rabbits. The investigators documented the 
accumulation of radiolabeled liposomes in plaque via single-photon 
emission computed tomography (SPECT) images. In the resulting SPECT 
images of harvested aorta 48 h after injection of liposomes, atherosclerotic 
regions were easily identified. Given that this method relies on the 
engulfment of liposomes by macrophages, it is important to maintain the 
size of the liposomes at <100 nm to achieve successful uptake [35]. 
PS is recognized by the glycoprotein CD36 receptors expressed on the 
macrophage. There are other ligands specific to the CD36 receptor, such 
as Hexarelin, which could be bound to the surface of liposomes and aid 
macrophage uptake of the liposomes [36].  ehT C-terminal globular domain 
of adiponectin (gAd) could also have a role in targeting. It binds efficiently 
to atherosclerotic plaques because of the presence of adiponectin receptors 
on macrophages. In addition to being useful in targeting, gAd and 
adiponectin have antiatherosclerotic effects, because they stimulate nitric 
oxide (NO) production by endothelial cells and have been shown to 
prevent the expression of the mRNA for VCAM-1 and ICAM-1 in rabbit 
atherosclerotic plaques. 
The apolipoprotein E-deficient (ApoE–/–) mouse model has been used to 
study the effects of liposomes on atherosclerosis. These genetically 
engineered mice lack the ApoE gene, and develop severe 
hypercholesterolemia and atherosclerotic lesions when consuming a 
cholesterol-rich chow diet [37–40]. Fluorescence images of an aortic 
sample taken from atherosclerotic ApoE–/– mice revealed the accumulation 
of gAd-functionalized liposomes in plaques. Fluorescent signals were 
evident in the plaque regions of aorta incubated with the gAd-
functionalized liposomes. The gAd liposomes demonstrated a significantly 
stronger signal compared with free gAd. This was thought to occur 
because the gAd-liposomes accumulated on the surface of plaque, whereas 
free gAd penetrated deeper into the plaque [41,42]. 
Folate receptor beta (FRβ) on the surface of activated macrophages in 
vulnerable plaques is another agent that could be exploited for the 
targeting of liposomes [43]. Various other receptors on macrophages can 
also be used for the purpose of liposome targeting. For instance, coating 
liposomes with a peptide sequence such as GGPNLTGRW (GGP-peptide) 
results in selective association with monocytes. Karathanasis et al. 
showed a >30-fold increase in the association of GGP-peptide-coated 
liposomes with monocytes compared with noncoated liposomes [44]. 
Decorating the liposome surface with the RGD tripeptide improves its 
association with integrin receptors expressed by monocytes [44–49]. Fc 
receptors on the surface of macrophages, especially the FcγRI receptor, 
are involved in phagocytosis. Fc-receptor-mediated phagocytosis enhances 
the uptake of liposomes by monocytes and macrophages, because 
immunoglobulins (immune liposomes) are recognized by these receptors 
[50]. Macrophages also express high levels of the mannose receptor (MR, 
CD206); therefore, attaching a MR ligand to the liposomes directs them 
towards the fibrous cap [51–56]. 
Targeting the fibrous cap of advanced plaques 
The fibrous cap comprises collagen, proteoglycans, and smooth muscle 
cells. The fibrin in the cap can be used as a target for liposomes. Demos et 
al. performed an in vitro study in which a liposomal formulation 
comprising phosphatidylcholine (PC), 4-(p-maleimidophenyl) butyryl 
phosphatidylethanolamine (MPB-PE), phosphatidylglycerol (PG), and 
cholesterol was conjugated to rabbit antihuman fibrinogen. This liposomal 
formulation successfully targeted fibrin-coated filter paper and slides. 
Attaching immune-labeled liposomes to the fibrin was confirmed by 
scanning electron microscopy (SEM). Subsequently, the evaluation of the 
aforementioned liposomes in an animal model of atherosclerosis revealed 
that antibody-conjugated liposomes specifically attached to the atheroma 
and not to the normal arteries [57]. Two years later, the same team 
targeted fibrous sections of the atheroma in Yucatan mini-pigs by 
conjugating antifibrinogen to the surface of liposomes [58]. To optimize 
the targeting potential of antifibrinogen-conjugated liposomes and their 
retention at the atheroma site, binding was studied under a variety of 
flow conditions (i.e., various shear stresses and temperatures). It was 
shown that this attachment was stable under nearly all of the conditions 
mimicking in vivo blood flow [59]. 
Diagnostic applications of liposomes in atherosclerosis 
Previously, the diagnosis of atherosclerosis was limited to methods such 
as assessment of electrocardiography at rest and during exercise, 
assessment of the ankle-brachial index, and invasive angiography. Today, 
visualizing plaques is possible through non-invasive imaging techniques 
[60]. Plaque imaging techniques in clinical use include ultrasound, 
magnetic resonance imaging (MRI), and computed tomography (CT), as 
well as nuclear imaging techniques, such as positron emission 
tomography (PET) and SPECT. In these techniques, liposomes act as 
diagnostic agents for the non-invasive early detection of atherosclerosis. 
Liposomal imaging agents provide signals directly from the lesion site. 
This allows the plaque to be detected and for inferences to be made about 
its size and composition. The most important role of liposomes in the 
diagnosis of atherosclerosis is to carry and deliver contrast agents, 
thereby improving image resolution. The liposomes can be made 
multifunctional by the simultaneous loading of multiple contrast agents. 
A range of imaging techniques are available (Figures 2–5) and the 
choice of the specific approach depends upon the developmental stage of 
the plaque being visualized. Early endothelial dysfunction can be 
diagnosed using functional measurements, such as peripheral artery 
tonometry, flow-mediated dilatation, and pulse wave velocity, and can be 
visualized using PET and CT. More advanced lesions with lipid 
accumulation can be observed using coronary intravascular ultrasound, 
MRI, and coronary CT angiography. Advanced plaques can be seen using 
electron-beam-CT [61] (Figure 6).  
Nuclear imaging (PET and SPECT) 
Nuclear imaging techniques rely upon a source of radiation within the 
body. Both SPECT and PET techniques construct images based upon the 
detection of gamma rays emanating from radioactive substances within 
tissues. 18F-fluorodeoxyglucose (FDG) is a radio-labeled glucose analog 
that can be used in PET scanning. In the context of atherosclerosis, this 
technique is useful in identifying macrophages and inflammation [62]. 
18F-sodium fluoride is another PET radiotracer that is used for dynamic 
evaluation of coronary microcalcification [63]. SPECT can also be used 
with a variety of tracers to identify inflammation [62]. Liposome-based 
probes are currently under investigation to enhance SPECT and PET 
imaging in a range of diagnostic settings. For example, PS-containing 
liposomes of 100 or 200 nm (PS100 and PS200) were injected into 
Watanabe heritable hyperlipidemic rabbits, scanned with SPECT and 
compared with CT images 48 h after injection (Figure 2) [64]. 
CT 
CT is an X-ray-based imaging technique that is fast and relatively 
inexpensive. However, in this method of detection, a bolus injection of 
contrast agent is required. CT angiography is suitable for the detection of 
calcification in atherosclerosis. With CT, liposomes have a similar role to 
that in MRI. Liposomes (either simple or PEGylated) typically carry a CT 
contrast agent ,such as iopromide, gold, or bismuth [65–68]. 
Danila et al. encapsulated a contrast agent called 5-[N-acetyl- (2,3-
dihydroxypropyl)-amino)-N,N-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-
benzene-1,3dicarboxamide (iohexol) into PEGylated liposomes with the 
aim of overcoming the short residence time and renal toxicity of free 
iohexol. The liposomes comprised dipalmitoyl phosphatidylcholine 
(DPPC), cholesterol, and a linker (molar ratio of 3:1:0.3) and were then 
conjugated to an antibody against ICAM-1 to target the plaque (Figure 3) 
[69]. 
MRI 
MRI is a useful approach for the detection of various plaque components, 
including the fibrous cap and lipid core. It provides information on plaque 
volume, composition, endothelial permeability, and plaque 
neovascularization, as well as 3D images of the plaque at near-cellular 
resolution. Thus, MRI has proven useful for the detection of macrophages 
and macrophage-rich areas in atherosclerotic plaques. Targeting 
liposomes to the plaque enables increased accumulation of loaded contrast 
agent at the plaque site, which results in improved signal strength 
(Figure 4). 
An example of liposomes that contain an MRI contrast agent are 
PEGylated liposomes into which gadopentetate dimeglumine (Gd-DTPA) 
has been incorporated [70,71]. In addition, as mentioned earlier, PS-
enriched liposomes are recognized by macrophages located in plaques. 
Thus, loading gadolinium into such liposomes increases its concentration 
at the site of the plaque [72]. The mechanism responsible for the 
accumulation of gadolinium-loaded liposomes in plaque has been 
attributed to EPR [73]. Gadolinium has also been loaded into liposomes 
functionalized with antibodies against LOX-1 receptors in the 
dysfunctional endothelium of plaque [24]. 
Other examples of liposomes containing gadolinium and detected with 
the use of MRI include work by Paulis et al., in which Gd-tetraxetan (Gd-
DOTA) and distearoyl phosphatidylethanolamine (DSPE) were used to 
facilitate ICAM-1 targeting [20]. In another study using MRI, an 
antagonist of integrin α4β1 (THI0567) was loaded into Gd-containing 
liposomes. This liposomal formulation binds to the integrin α4β1 (very 
late antigen-4, VLA-4) receptors on monocytes and was used to identify 
plaque in the aortas of atherosclerosis-prone ApoE–/– mice [74]. In 
summary, targeted liposomes containing gadolinium-based contrast 
agents produce low background enhancement and are suitable for MRI of 
endothelial markers that are abundant inside plaque deposits [75]. 
Ultrasonography 
Ultrasound imaging techniques are beneficial for the detection of 
vulnerable atherosclerotic plaques. Using ultrasound, it is possible to 
perform a catheter-based, real-time measurement of carotid intima-
media thickness. Emerging techniques, such as intravascular 
photoacoustic-ultrasound (IVPA-US) imaging, can provide more precise 
information concerning the morphology of the arterial wall. The major 
advantage of IVPA-US over conventional ultrasound methods is that it 
can provide information on the composition of the plaque [76,77]. 
The layered structure of liposomes allows for the entrapment of gas 
bubbles, which efficiently reflect sound waves and produce ‘acoustically 
reflective’ liposomes. Such acoustically reflective liposomes can be 
attached to antibodies (antifibrinogen or anti-ICAM-1) to enable the 
recognition and targeting of plaque. Multilamellar acoustic liposomes 
have been prepared that comprise phosphatidylcholine, 
phosphatidylethanolamine, phosphatidylglycerol, and cholesterol, with 
entrapped gas bubbles between the lipid layers. This resulted in a 
significant acoustic enhancement during ultrasound imaging when 
evaluated in the Yucatan mini-swine model of induced atherosclerosis 
(Figure 5) [58,78]. An alternative approach to the IVPA-US method is to 
include a contrast agent, such as indocyanine green (ICG) J-aggregate 
(IJA), into liposomes. Such liposomes have been targeted towards FRβ, 
which is overexpressed on activated macrophages in atheromatous 
plaque. Increased uptake of FRβ-targeted liposomes was evident in vivo 
using an ApoE–/– mouse model of atherosclerosis [43]. 
Roles for liposomes in the treatment of atherosclerosis 
Liposomes as cholesterol-lowering agents 
Given that the deposition of cholesterol results in plaque progression, 
reducing the concentration of circulating cholesterol is a routine 
therapeutic approach in the treatment of atherosclerosis. In one study of 
the expression of genes involved in the efflux of cholesterol in an LDLR–/– 
mouse model in which the mice consumed a cholesterol-rich diet showed 
that nanoliposomes upregulated ATP binding cassette subfamily A 
member 1 (ABCA1) and subfamily G member 1 (ABCG1) genes. These 
genes encode cholesterol transporter proteins. Liposomes containing 
anionic phospholipids, such as hydrogenated soy phosphatidylcholine 
(HSPC) and distearoyl phosphatidylglycerol (DSPG), have the ability to 
enhance reverse cholesterol transport. This means that liposomes can 
take up cholesterol and return it to the liver for reuse or excretion in the 
bile. Reverse cholesterol transport decreases the availability of cholesterol 
at the vascular wall and thereby decreases the production of foam cells 
[79–83]. ABC transporters act as a mediator of the cholesterol efflux 
pathways and result in antiatherogenic effects. Additionally, ABC 
transporters control the proliferation and mobilization of hematopoietic 
stem and progenitor cells in the bone marrow. Hence, activation of 
cholesterol efflux pathways suppresses the mobilization of stem cells and 
hematopoiesis, which consequently lowers the production of monocytes 
and macrophages. Thus, inflammation, an important contributor to the 
pathogenesis of atherosclerosis, is attenuated [84]. 
In another interesting study, high-density lipoprotein (HDL) was 
adsorbed onto PS-containing liposomes (synthetic 
dimyristoylphosphatidylcholine). After 5 weeks of infusion of such 
liposomes into cholesterol-fed rabbits, aortic cholesterol content was 
significantly reduced. This was attributed to the high affinity of 
macrophages for PS, leading to the accumulation of liposomes containing 
HDL at the macrophage-rich plaque site, and then HDL subsequently 
carrying cholesterol away from the plaque site [85]. 
Liposomes as drug delivery carriers 
Liposomes and nanoliposomes are interesting candidates for drug delivery 
applications because of their ability to entrap both hydrophilic and 
hydrophobic drugs. Biocompatibility, low toxicity, and high loading 
capacity make liposomes useful as drug carriers. Typically, the surface of 
liposomes is modified with PEG to prevent aggregation and rapid 
systemic clearance [71]. 
Liposomes were the first drug delivery system with clinical applications. 
The benefits of combining drugs with liposomes include; increased 
biodistribution of the entrapped drug, improved therapeutic index 
(achieved by altering the pharmacokinetics and pharmacodynamics of the 
drug), and prevention of drug degradation by components of plasma. Some 
clinically approved liposomal formulations include Doxil® for the 
treatment of ovarian cancer, DaunoXome® for the treatment of advanced 
HIV-associated Kaposi’s sarcoma, Depocyt®, Myocet®, Mepact®, and 
Marqibo® for cancer management, Onivyde™ for metastatic 
adenocarcinoma of the pancreas, Amphotec® and Ambisome® for the 
treatment of fungal infections, Visudyne® for photodynamic light therapy, 
DepoDur™ for pain management and for use as an anesthetic agent, and 
Epaxal® and Inflexal® for vaccination against hepatitis and influenza, 
respectively. Although Liprostin™ for the treatment of restenosis 
subsequent to angioplasty is in Phase III clinical trials, no liposomal 
formulations for atherosclerosis are currently available on the market 
[86]. 
In the context of treating atherosclerosis, liposomes can be used to 
improve the solubility of drugs, increase their half-life in the circulation, 
and enable selective or targeted delivery of the drug to the site of 
atherosclerotic plaque. The surface of liposomes can be modified with 
antibodies or ligands to target the endothelium of the atherosclerotic 
plaque or the macrophages recruited therein, such that healthy cells are 
not affected [87]. 
Liposomes release drug when they interact with cells. Given that the 
cell membrane, similar to liposomes, comprises phospholipids, liposomes 
fuse with the cell membrane easily. After attachment, the fused liposomes 
are degraded by lipase enzymes and release their contents. 
Physicochemical characteristics of nanoliposomes and liposomes, 
including lipid composition, size, fluidity, net surface charge, steric 
stabilization, dose, and route of administration, influence the interaction 
of cells and liposomes and, consequently, affect the pharmacokinetics of 
the drugs they carry. Incorporation of cholesterol within liposomes could 
influence their rigidity and uptake by cells. As mentioned earlier, the 
physicochemical properties of the encapsulated drug also affects how it is 
released. The value of the octanol/buffer partition coefficient of drugs 
determines whether prolonged or rapid release of the drug occurs. The 
drug:lipid ratio is another factor that determines the rate of release of the 
incorporated drug [71,87]. 
Liposomes have been investigated as potential carriers for a range of 
drugs with potential therapeutic benefits in atherosclerosis, including 
anti-inflammatory and antiangiogenic drugs. Some of these studies are 
described below. 
Anti-inflammatory drugs Glucocorticoids are widely studied anti-
inflammatory agents for the treatment of atherosclerosis and can be 
loaded into liposomes. Loading glucocorticoids into liposomal carriers 
reduces the adverse effects when dosed by the oral route, which include 
diabetes mellitus, osteoporosis, and hypertension. Additionally, loading 
glucocorticoids into liposomes and administering them via the oral route 
prevents problems associated with the systemic injection of 
glucocorticoids, which include a very short circulating half-life and 
suboptimal disposition of the incorporated glucocorticoids in vivo (i.e., the 
associated pharmacokinetic parameters). Thus, these limitations often 
necessitate the frequent intravenous administration of glucocorticoids at 
high doses. Loading glucocorticoids into PEGylated liposomes increases 
the circulation time and improves their accumulation in atherosclerotic 
lesions [88]. In a study by Lobatto et al., glucocorticoids were loaded into 
PEGylated nanoliposomes and tested in a rabbit model of atherosclerosis. 
The accumulation of drug in the plaque and its anti-inflammatory effects 
were evaluated using MRI, because some of the ingredients in the 
nonliposomal formulation contained gadolinium to serve as the contrast 
agent for MRI analysis. It was demonstrated that, 2 days after 
administration, gadolinium-labeled liposomes accumulated in the 
atherosclerotic lesions and increased the intensity of the MRI signal [89]. 
It was suggested that the EPR effect had a significant role in the 
targeting of plaque by the glucocorticoid-containing PEGylated 
nanoliposomes used in this study [89]. 
Prednisolone phosphate is a synthetic glucocorticoid that has beneficial 
effects against atherosclerosis when incorporated into liposomes. 
PEGylated liposomes containing prednisolone phosphate were 
successfully used to target atherosclerotic lesions in a rabbit model of 
atherosclerosis [89]. Joner et al. encapsulated the same drug into 
PEGylated liposomes comprising HSPC, cholesterol, and TRX-20 (3,5-
dipentadecyloxybenzamidine hydrochloride) at a molar ratio of 50:42:8. 
This liposome showed high affinity for subendothelial proteoglycans. The 
cationic lipid component of TRX-20 facilitates endocytosis of the liposome 
and subsequent release of the drug inside the cell. Intravenous 
administration of this formulation in a rabbit model of atherosclerosis 
reduced the percentage of the ‘in-stent’ stenosis area, the inflammation 
score, infiltration of giant cells, and the percentage of the neo-intima 
occupied by macrophages [90]. 
Despite these promising therapeutic effects of prednisolone-loaded 
liposomes, lipotoxicity can be generated by liposomes, which has the 
potential to exacerbate the degree of atherosclerosis. It was reported that, 
2 weeks after infusion of liposomes loaded with prednisolone, the number 
of inflammatory cells and the area of the necrotic core had increased. 
Moreover, existing plaques had progressed to a more advanced stage. In 
this case, increased recruitment of monocytes to the site of the plaque, as 
well as the increased expression of ER-MP58, a characteristic of 
circulating immature myeloid cells, were observed. Prednisolone-loaded 
liposomes might confer a benefit to counteracting inflammation at the site 
of atherosclerotic lesions, but only if the dose and duration of therapy can 
be optimized [91]. The first clinical study of prednisolone-loaded 
PEGylated liposomes in humans was conducted in 2015. Administration 
of this formulation (1.5 mg/kg) resulted in an increased plasma half-life of 
prednisolone of 63 h. In this clinical study, liposomes successfully 
accumulated in atherosclerotic plaque, but inflammation of the arterial 
wall was not reduced. This was suggested to result from either an 
insufficient dose of prednisolone at the plaque site or from an inadequate 
duration (i.e., 10 day duration) of the prednisolone at the plaque site to 
elicit optimal anti-inflammatory effects. Interestingly, it has been shown 
that even empty liposomes can absorb intracellular cholesterol and 
facilitate the regression of atherosclerosis [92]. 
In addition to prednisolone, other drugs can be incorporated into 
liposomes for the treatment of atherosclerosis. As an example, anti-
inflammatory corticosteroids can be targeted locally to the site of 
inflammation through the use of liposomes. A local anti-inflammatory 
effect is advantageous, because it negates the need for the induction of 
systemic immunosuppression and the associated adverse off-target effects 
that result. A liposome formulation comprising a mixture of DPPC, 
cholesterol, and PEG 2000 DSPE was used to load a water-soluble 
corticosteroid derivative into the aqueous interior of the structure [88,89]. 
Other attempts to utilize anti-inflammatory compounds in liposomes to 
treat the inflammation associated with atherosclerosis include the use of 
anti-inflammatory cyclopentenone prostaglandins. The prostaglandins 
were loaded into liposomes and were shown to be beneficial in a mouse 
model of atherosclerotic vascular injury [19]. Dexamethasone is another 
drug that has been incorporated into liposomes for the treatment of 
atherosclerosis. Liposomes in this study were formed from egg yolk 
phosphatidylcholine, cholesterol, and dicetylphosphate. Administration of 
this formulation to atherogenic mice once a week for 8–14 weeks reduced 
the level of aortic cholesterol ester, which was suggested to result from 
the antiatherosclerotic effects of the dexamethasone-loaded liposomes 
[93]. 
Given the potential of antagonists of chemokines involved in the 
development of chronic inflammation to reduce inflammation and 
atherosclerosis, PEGylated liposomes have been loaded with chemokine 
receptor antagonists (Teijin compound 1) and targeted against activated 
endothelium. When released, the antagonists occupied the binding sites 
for chemokines and, consequently, blocked the pathway responsible for 
cytokine-mediated inflammation. Targeting was achieved by binding a 
specific peptide to the liposomes that subsequently bound to endothelial 
VCAM-1. A mixture of dioleoyl phosphatidylethanolamine (DOPE), 
dioleoyl phosphatidic acid (DOPA), and maleimide-PEG-DSPE was used 
to prepare the liposomes. Upon reaching the target, liposomes fused with 
the cell membrane, collapsed, and released their contents. In experiments 
with ApoE–/– mice, this approach resulted in a reduction in the size of 
atherosclerotic lesions [94]. Other bioactive compounds and/or drugs 
considered for liposomal plaque targeting include the liver X receptor 
(LXR) agonist T09, simvastatin, and pterostilbene. These compounds 
significantly inhibit NF-B activity, suppress the proliferation of 
macrophages, and confer antioxidant activity [95]. Delivery of the 
compound T0901317, an agonist of LXR receptors found on macrophages, 
using cationic liposomes has been shown to exert atheroprotective effects 
by increasing the efflux of cholesterol from macrophages. This protective 
effect results from a threefold increase in the expression of cholesterol 
efflux genes; specifically, ABCA1 and ABCG1, when liposomes containing 
LXR receptors antagonists were evaluated in ApoE–/– mice [96]. 
Antiangiogenic drugs Drug-loaded liposomes also have the potential to 
reduce angiogenesis within plaques. Incorporation of bevacizumab (BEV), 
a US Food and Drug Administration (FDA)-approved monoclonal antibody 
to vascular endothelial growth factor (VEGF), into liposomes has the 
potential to reduce atherosclerosis. This antibody inhibits the expression 
of VEGF, neovascularization, and the progression of atherosclerosis. 
Given that systemic delivery of BEV is accompanied by adverse effects, 
such as bleeding, arterial thrombosis, and hypertension, the use of BEV-
containing liposomes as a carrier would appear to be a logical approach. 
Interestingly, a 5-min exposure of HUVECs to 15-MHz ultrasound 
accelerated the release of BEV from the liposomes. As a result, VEGF 
expression was reduced by 90% [97]. Lastly, fumagillin, a selective 
inhibitor of endothelial cell proliferation and migration, which is able to 
prevent the expansion of the vascular network, has been incorporated into 
liposomes and targeted to plaque [98]. 
Liposomes as vaccines 
Given that components of the immune system are involved in 
atherosclerosis, the course of the disease can be altered by modulating 
immune responses. The immune system can be deliberately activated in 
response to specific antigens given as vaccines. The goal of vaccination is 
to enhance the response of the immune system to pathogens. Liposomes 
have the potential to be immunogenic, either by targeting antigens 
toward the immune system, or by acting as antigens themselves. The 
release of antigens from circulating liposomes produces a long-lasting 
humoral immune response. After administration of liposomes into the 
body, either through systemic delivery or using other routes of 
administration, such as nasal or transcutaneous, the body immunizes 
itself against the liposome-loaded antigen [99–101]. In fact, phagocytosis 
by macrophages of antigen incorporated into liposomes leads to the 
accumulation of antigens in the lysosome. In lysosomes, the peptide is 
degraded and presented to the major histocompatibility complex class II 
(MHCII) on the surface of the macrophage. As a result, T helper cells and 
specific B cells are activated and antibodies are secreted [102]. 
Administering high doses of plaque-specific antigens both stimulates and 
initiates a regulatory T cell (Treg) response. The Tregs exert protective 
effects in atherosclerosis by reducing chronic inflammation via secretion 
of anti-inflammatory cytokines, such as IL-10 and transforming growth 
factor (TGF)-β. Liposomes could be used to stimulate cells to increase the 
secretion of immune suppressive agents, such as immunoglobulin (Ig)M. 
There is some evidence that the IgG-producing B2 cell subset increases 
plaque progression and atherosclerosis. However, by contrast, it has been 
demonstrated that B cells are antiatherogenic because of the production of 
IgM antibody [81]. A variety of plaque specific antigens have been 
investigated and these are described below. 
Phosphatidylserine plaque-specific antigen The first plaque-specific 
antigen incorporated into liposomes was PS. Hosseini et al. developed PS 
liposomes that mimic apoptotic cells, which are known to be immunogenic 
and anti-inflammatory. Similar to apoptotic cells that express double-
stranded (ds) DNA, which activates toll-like receptor 9 (TLR9) on B1a, PS 
activates TIM1/4 (a molecule that recognizes PS). This activation results 
in the mobilization and expansion of atheroprotective B1a cells in the 
peritoneum, as well as an elevation in the production of IgM. 
Intraperitoneal injection of synthetic PS liposomes in ApoE–/– mice leads 
to a reduction in overall atherosclerotic plaque size, as well as the size of 
the necrotic core, plaque macrophage and T cell content, and cytokine 
expression. The precise mode of action of PS liposomes in atherosclerosis 
is not clear [103]. PS liposomes have some advantages over the use of 
human primary or immortalized cells utilized for other chronic 
inflammatory or autoimmune diseases. First, liposomes can be produced 
in a more controlled manner and on a larger scale. Second, they are 
associated with lower health risks. PC head groups in the liposome 
structure, which also exist on the surface of apoptotic cells, are another 
plaque-specific antigen. It has been reported that production of anti-PC 
antibodies increases levels of IgM and reduces atherosclerosis [104]. 
Lipoprotein plaque-specific antigens LDL and apoB-100 (the 
apolipoprotein of LDL) have been used as plaque-specific antigens and 
incorporated into liposomes. ApoB100 is a protein surrounding LDL and 
contains several potential CD4+ T cell epitopes. LDL itself is a large and 
heterogeneous molecule; therefore, antigenic epitopes in LDL include 
~102 peptides. As an alternative, a peptide derived from apoB-100 can be 
used [104]. In one study, liposomes containing the anionic phospholipid 
DSPG were loaded with apoB-100. The first step involves attachment of 
complement component 1q (C1q) to the surface of the anionic liposomes, 
which can then be recognized by scavenger receptors on phagocytic cells 
and subsequently taken up by the phagocytic cells. Immunization with 
these peptides initiates CD4+ T cell responses and, thereby, vaccinates 
the body against atherosclerosis. In a study by Benne et al., 10 nmol of 
this vaccine was shown to decrease plaque formation by 50% and reduce 
serum cholesterol concentrations in LDLR–/– mice. Importantly, 
administration of the vaccine resulted in increased antigen-specific CD4+ 
T cell proliferation after 7 days [105]. 
Peptide plaque-specific antigens The peptides ovalbumin-derived CD4+ T-
cell-specific peptide (OVA323) and proprotein convertase subtilisin/kexin 
type 9 (PCSK9) are plaque-specific antigens that have also been 
incorporated into liposomes. Production of antibodies against these 
peptides increased after administration of peptide-loaded liposomes. 
Liposome-loaded OVA323, in comparison to free OVA323, resulted in an 
increase in the proliferation of Tregs [106]. Additionally, PCSK9-loaded 
liposomes induced anti-PCSK9 production. This antibody disrupts the 
interaction between PCSK9 and LDLR, which leads to metabolism and, 
thus, a lowering of plasma LDL cholesterol. Forty-eight weeks after 
subcutaneous inoculation of this formulation into BALB/c mice, plasma 
PCSK9 concentration were decreased by nearly 50% and the PCSK9–
LDLR interaction was inhibited. Anti-inflammatory T cells (CD4+ and IL-
4+) increased, whereas the number of proinflammatory cells remained 
unchanged. The negative surface charge of liposomes enhances the 
humoral immune response to surface-exposed peptide antigens, because 
these antigens are better recognized by B cell receptors and give rise to 
more efficient antibody production [34]. 
Cholesterol plaque-specific antigens Immunization against cholesterol is 
another strategy against atherosclerosis. Liposomes containing 71% 
cholesterol have been shown to induce anticholesterol antibodies. These 
antibodies capture the cholesterol in circulating lipoproteins, which 
results in a mean decrease in serum cholesterol of 35%. In fact, 
immunization of hypercholesterolemic rabbits using this technique 
resulted in a reduction of atherosclerosis [107]. In another similar study, 
liposomes containing cholesterol were injected into rabbits that had been 
fed 2 g/day of cholesterol, 5 days a week for a duration of 18 weeks. At 
autopsy, the extent of atherosclerotic plaques in the heart and aorta was 
measured. It was shown that even after cholesterol feeding, the reactivity 
of anticholesterol antibodies increased in the serum after liposome 
injection and this resulted in a dramatic reduction in serum cholesterol. 
Additionally, no atherosclerotic plaques were formed in the aortic intima 
of rabbits immunized with these liposomes [108]. 
Liposomes as stem cell carriers 
In atherosclerosis, damaged tissue repair is prevented by apoptosis and 
the loss of vascular stem cells. Therefore, transplantation of exogenous 
stem cells helps the vascular tissue to repair and prevents plaque rupture. 
Stem cells can differentiate into neo-intima smooth muscle cells or 
endothelial cells and enable the recovery of vessel function. Direct 
injection of stem cells to the lesion site has poor therapeutic results. 
However, liposomes have been used as a carrier for stem cells. For this 
purpose, liposomes have been modified with two antibodies, one for CD34 
antigens on the surface of stem cells and the other for ICAM-1 (Figure 7). 
After liposomes containing stem cells have reached the atheromatous 
plaque, the cells can be conveniently separated from the liposomes using a 
sonoporation technique. In this method, a 1-MHz low-amplitude 
continuous ultrasonic wave is used to break the gas bubbles between the 
lipid bilayers of the liposomes, which creates cavities in the liposomes and 
allows the release of the stem cells [109,110]. 
Liposomes as nonviral gene delivery vectors 
Delivery of specific genes to the site of plaque formation could stop the 
progression of atherosclerosis. Nanoliposomes can be used as nonviral 
vectors for the delivery of therapeutic mRNA to cells, which enables the 
transfection of cells with specific genes. This overcomes the problem of the 
short half-life of mRNA, as well as to protect the sensitive structure of 
siRNA from degradation by serum RNases [111]. In one study, liposomes 
were used as a small interfering (si)RNA delivery system to achieve a 
reduction in the expression of fatty acid binding protein 4 (FABP4). The 
liposomal carriers were labeled with quantum dots to enable their 
biodistribution to be mapped in the aorta after intravenous injection in 
mice. Immunofluorescent staining demonstrated successful uptake of 
liposomal siRNA into atherosclerotic plaque and the silencing of FABP4 
[112]. Additionally, targeted delivery of siRNA of endothelial gene VE-
cadherin to activated endothelial cells has been investigated. Given the 
negative charge of siRNA, cationic liposomes from amphiphilic SAINT-
C18 [1-methyl-4-(cis-9-dioleyl) methyl-pyridinium-chloride] were 
formulated and their surface was modified with anti-VCAM-1 and anti-E-
selectin for more efficient targeting of endothelial plaque, as well as for 
upregulation of the VE-cadherin gene (Figure 8) [113]. 
Gene delivery using liposomes could prevent graft atherosclerosis, a 
common problem limiting the long-term success of cardiac 
transplantation. Graft atherosclerosis is induced because of a decrease in 
the level of tissue plasminogen activator (tPA) in the arteriolar smooth 
muscle cells. Gene delivery, with the goal of overexpressing tPA, could 
reduce the risk of atherosclerosis. Cationic liposomes comprising (+/–)-N-
(3-aminopropyl)-N,N-dimethyl-2,3-bis(dodecyloxy)-1-propanaminium 
bromide (GAP: DLRIE) have been used for the incorporation and 
subsequent delivery of tPA cDNA. Intracoronary infusion of this complex 
in a rabbit heterotopic cardiac transplant model resulted in increased 
expression of the tPA gene in the vascular wall and inhibited the 
progression of atherosclerosis [114]. 
As it pertains to gene delivery, physicochemical parameters, such as the 
size and charge of liposomes, determine the rate of uptake by cells at the 
plaque site. Some evidence suggests that liposomes <100 nm have longer 
circulating half-lives and, therefore, better accumulation in plaque. 
Uptake of such liposomes by the mononuclear phagocytic system (MPS) 
has been shown to be improved. Conversely, other studies have found 
improved MPS uptake when the size of the liposomes was increased. 
Negatively charged liposomes internalize more readily, because they are 
more easily recognized by macrophages [115,116]. In an atherosclerotic 
plaque, macrophages are the metabolically active regions. One study 
investigating the uptake of anionic liposomes into atheromas using 
Watanabe heritable hyperlipidemic rabbits showed that the uptake of 
anionic liposomes was improved in the metabolically active sites of the 
plaque [117,118]. In general, anionic liposomes cannot pass through the 
endothelial barrier because of electrostatic repulsion of like charges. 
However, because the endothelium of atherosclerotic plaques is 
dysfunctional, the permeability is increased. Injecting fluorescently 
labeled liposomes into ApoE–/– mice led to accumulation of the liposomes 
in lipid-rich areas of atherosclerotic plaques and, subsequently, into 
macrophages. A study of human coronary artery endothelial cells 
pretreated with an inhibitor of clathrin-mediated endocytosis 
demonstrated that clathrin-mediated endocytosis is the pathway 
responsible for the uptake [40]. One difference between anionic and 
cationic liposomes is that cationic liposomes can induce cytotoxicity, 
cytokine activation, and proinflammatory effects. Despite these 
limitations, cationic liposomes are more suitable for gene delivery 
applications. The positive charge on these liposomes facilitates 
electrostatic interaction with negatively charged proteoglycans on the cell 
membrane. Therefore, delivery of a gene to the cell is enhanced [105,119]. 
Concluding remarks and future direction 
We have reviewed the potential role of liposomes and nanoliposomes in 
the diagnosis of atherosclerosis. The research to date suggests that 
liposomes are suitable for carrying and concentrating CT and MRI 
contrast agents into the site of plaques to sufficiently enable high-quality 
imaging. To increase the precision and resolution of plaque imaging, a 
combination of different imaging techniques can be used. Liposomes are a 
good candidate for this purpose because of their multilayered structure, 
which enables the simultaneous incorporation of different hydrophobic 
and hydrophilic contrast agents. Additionally, this feature of liposomes 
makes them attractive for the codelivery of drugs and contrast agents by a 
single liposomal formulation. This strategy, referred to as theranostics, is 
an emerging field in which the effects of a therapeutic agent can be 
monitored after it has been administered to the patient. 
The potential application of liposomes to the management of 
atherosclerosis was also reviewed. Liposomes have been used successfully 
to deliver genes, stem cells, and anti-inflammatory or antiangiogenic 
drugs to the plaque site. Administration of liposomes has been shown to 
lower LDL cholesterol, and liposomes have been used to produce vaccines 
against atherosclerotic mediators. Targeting liposomes to the plaque site 
has been achieved using various strategies, which are discussed in this 
review and are shown in XXX. The targeting of liposomes to macrophages 
has been extensively studied, but no study to date has investigated the 
targeting of liposomes to enzymes or proteins that are oversecreted by 
macrophages at the plaque site. A future approach might be to use matrix 
metalloproteinases (MMPs) produced by macrophages to target 
liposomes to macrophages. The increased concentration of MMPs at the 
site of atheromatous plaques makes the plaque more vulnerable to 
rupture [120]. Therefore, loading MMP inhibitors into liposomes would 
not only target them toward MMP-rich regions in the vessel (i.e., 
plaque), but also reduce MMP levels and potentially prevent plaque 
rupture. 
Liposomes have many advantages over other materials used in 
nanomedicine. They have the potential for the clinical management of 
atherosclerosis. However, much of the research to date has been 
conducted in laboratory settings, or in small clinical studies. Therefore, 
the potential to draw major inferences relating to the clinical treatment of 
patients is limited. Proof-of-concept studies, which demonstrate improved 
delivery of therapeutic agents to specific sites of atherosclerotic activity, 
do not necessarily imply improved clinical effectiveness and provide no 
guarantee against unexpected harm that might result from any new drug 
or therapeutic technology. Ultimately, similar to all novel therapies, the 
benefits need to be evaluated in terms of both safety and cost. 
Nevertheless, based upon available data, it would be prudent to be 
cautiously optimistic about the potential uses of liposomes in the 
diagnosis and treatment of atherosclerosis at this time. However, it would 
appear to be an appropriate time to move to large-scale trials to 
determine whether liposome-based imaging techniques can improve the 
prediction of cardiovascular risk when used in conjunction with the 
advanced imaging techniques that have now been developed and 
described in this review [121,122]. Moreover, it would seem logical to 
determine whether liposome-based therapeutics are more effective than 
currently available drugs for the treatment of atherosclerosis. Finally, the 
large-scale production of targeted liposomes with different ligands 
attached to their surface is another issue that urgently needs to be 
addressed. 
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Figure 1. A schematic representing strategies for targeting liposomes to 
atherosclerosis. Abbreviations: CAMs, cell adhesion molecules; EPR, 
enhanced permeability and retention; FRβ, Folate receptor beta; gAd, 
globular domain of adiponectin; IL-10, Interleukin-10; JAMs, junctional 
adhesion molecules; LOX-1, lectin-like oxidized LDL receptor-1; PS, 
phosphatidylserine;. 
Figure 2. Single-photon emission computed tomography (SPECT) and 
computer tomography (CT) images, ex vivo autoradiography, and 
histological images of 111In-PS100 (a) and 111In-PS200 (b) in Watanabe 
heritable hyperlipidemic (WHHL) rabbits and 111In-PS200 in normal rabbits 
(c). Arrows indicate the position of aorta. L indicates the liver. Magnified 
images of Azan-Mallory staining show macrophage foam cell-rich regions 
with fewer smooth muscle cells (dashed red circle) and a more fibrotic 
region with dead macrophages (dashed yellow circle). Atherosclerotic 
regions were successfully visualized with 111In-PS200 and 111In-PS100 in 
WHHL rabbits. Radioactivity accumulated in macrophage foam cell areas 
and was low in fibrotic areas. No aortic accumulation was seen in normal 
rabbits. 111In-PS100: Indium 111-labled liposome with 100 nm size. 
Reproduced from [35]. 
Figure 3. Title. Aortic wall enhancement by smaller liposomal contrast 
agent (d ~ 112 nm) in Watanabe heritable hyperlipidemic (WHHL) rabbits 
(a,b) and balloon-denuded cholesterol-fed New Zealand white (NZW) 
rabbits (c,d). Animals were injected intravenously with control liposomes 
[phosphatidylcholine (PC)-liposomes] (a,c) or phosphatidylserine (PS)-
liposomes (b,d). Imaging was performed with a GE eXplore flat-panel 
computer tomography (CT) scanner at baseline and 48 h after contrast 
injection. Section thickness was 0.2 mm and reconstructed images were 
displayed with a maximum intensity projection of 1.0 mm. Specific 
contrast enhancement in the aorta was determined by comparing images 
obtained at baseline and 48 h after injection. Focal enhancement was 
detected in the atherosclerotic segments in the aortas in both animal 
models injected with PS-liposomes (yellow arrows) but not with control 
liposomes. (e) CT enhancement of highlighted regions at baseline and 48 
h after injection of various liposomal preparations in both animal models. 
Reproduced, with permission, from [123]. 
Figure 4. Images of the delivery and localization of glucocorticoid-loaded 
gadolinium (Gd)-containing liposomes by magnetic resonance imaging 
(MRI) and confocal laser scanning microscopy. (a) In vivo MRI of the 
abdominal aorta before (left) and 2 days after (right) the administration of 
liposomes. A marked signal intensity increase was observed throughout 
the atherosclerotic lesion. (b) Near-infrared fluorescence images of an 
atherosclerotic aorta excised from a rabbit injected with liposomes (left) 
and untreated aorta (right). The color bar represents photon count. (c) 
Confocal laser scanning microscopy of liposomes (red), cell nuclei (blue), 
and macrophages. (d) A high degree of colocalization of liposomes with 
macrophages was observed. (e) Although liposomes were found 
throughout the entire lesion areas, a vessel wall reconstruction of multiple 
confocal laser scanning microscopy images revealed heterogeneous 
accumulation of liposomes. (f) The corresponding MRI slice of the 
histological section depicted in (e) revealed a similar heterogeneous 
distribution. Reproduced, with permission, from [89]. 
Figure 5. Transvascular ultrasound images of an atherosclerotic left 
carotid artery of a Yucatan mini swine. (a) After injection of saline. (b) 
After injection of antifibrinogen-labeled liposomes (arrows indicate 
liposomal attachment to fibrinogen in the atherosclerotic plaque). 
Reproduced, with permission, from [58]. 
Figure 6. The progression of atherosclerosis by different imaging 
modalities. This figure depicts how atherosclerosis begins with 
endothelial dysfunction, followed by expression of proadhesive molecules 
that recruit monocytes in response to stimuli such as hypertensive 
pressure or lipid build-up. These monocytes then take up lipids to become 
foam cells. Additionally, smooth muscle cells migrate from the tunica 
media to the tunica intima, where they produce elastin and collagen, 
which create a cap that covers the plaque. Plaque growth can 
compromise blood flow to distal regions, resulting in stable angina or 
peripheral arterial disease. Alternatively, erosion of the fibrous cap can 
expose prothrombotic mediators, resulting in clot formation and 
infarction, either in the myocardium or the brain. Imaging modalities for 
these stages should be selected based on the physiological changes 
expected at each stage. Abbreviations: CAC, coronary artery calcium; 
CT, computer tomography; FDG-PET, 18-fluorodeoxyglucose positron 
emission tomography; FMD, flow-mediated dilatation; IVUS, intravascular 
ultrasound; NaF, sodium fluoride; PAT, peripheral arterial tonometry, 
small arteries; PET, positron emission tomography; PWV, pulse wave 
velocity, large arteries. Reproduced, with permission, from [109]. 
Figure 7. Scanning electron microscopy of bifunctional echogenic 
immunoliposome (BF-ELIP)-targeted CD34+ cells adhering to the luminal 
surface of porcine aorta following ultrasound treatment. (a) Scattered cell 
attachment to normal, nonatherosclerotic aortic surface, and (b) 
increased cell attachment and penetration in region with fatty streaks. 
Arrows indicate BF-ELIP-stem cell complexes adhering to the aorta. 
Reproduced, with permission, from [109]. 
Figure 8. Effective downregulation of VE-cadherin in primary endothelial 
cells via targeted SAINT-O-Somes (cationic liposomes fabricated from 
amphiphilic SAINT-C18) small interfering (si)RNA delivery. Tumor necrosis 
factor (TNF)-α-activated human umbilical vein endothelial cells (HUVEC) 
and human aortic endothelial cells (HAEC) were incubated with targeted 
SAINT-O-Somes containing VE-cadherin (VE) or control siRNA (CS) at a 1 
μM concentration for 48 h. After incubation, RNA or cell lysates were 
used for RT-qPCR (a,b), ELISA (c,d), and western blot (e,f). (a,b) Data are 
presented as relative expression ± SD, compared with cells treated only 
with TNF-α (Ctr), of a minimum of three independent experiments. *P 
<0.05. (c,d). Data are presented as VE-cadherin protein expression ± 
SD of three independent experiments. (e,f) Images show a representative 
western blot. Reproduced, with permission, from [113]. 

